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ABSTRACT
Objective To assess whether it is feasible to establish
speciﬁc cut-off values able to discriminate ‘physiological’
or ‘pathological’ brain volume rates in patients with
multiple sclerosis (MS).
Methods The study was based on the analysis of
longitudinal MRI data sets of patients with MS (n=206,
87% relapsing–remitting, 7% secondary progressive and
6% primary progressive) and healthy controls (HC; n=35).
Brain atrophy rates were computed over a mean follow-up
of 7.5 years (range 1–12) for patients with MS and
6.3 years (range 1–12.5) for HC with the SIENA software
and expressed as annualised per cent brain volume
change (PBVC/y). A weighted (on the follow-up length)
receiver operating characteristic analysis and the area
under the curve (AUC) were used for statistics.
Results The weighted PBVC/y was −0.51±0.27% in
patients with MS and −0.27±0.15% in HC (p<0.0001).
There was a signiﬁcant age-related difference in PBVC/y
between HC older and younger than 35 years of age
(p=0.02), but not in patients with MS (p=0.8). The cut-
off of PBVC/y, as measured by SIENA that could maximise
the accuracy in discriminating patients with MS from HC,
was −0.37%, with 67% sensitivity and 80% speciﬁcity.
According to the observed distribution, values of PBVC/y
as measured by SIENA that could deﬁne a pathological
range were above −0.52% with 95% speciﬁcity, above
−0.46% with 90% speciﬁcity and above −0.40% with
80% speciﬁcity.
Conclusions Our evidence-based criteria provide values
able to discriminate the presence or absence of
‘pathological’ brain volume loss in MS with high
speciﬁcity. Such results could be of great value in a
clinical setting, particularly in assessing treatment efﬁcacy
in MS.
INTRODUCTION
Numerous recent studies have used MRI-based
methods for a computed estimation of brain
volumes, since this may represent a valid biomarker
of clinical state and progression in many neurological
disorders.1 In multiple sclerosis (MS), although the
pathological hallmark is the focal demyelination of
the cerebral white matter (WM), signiﬁcant brain
atrophy also occurs and proceeds relentlessly
throughout the MS course.2 3 These volumetric
changes occurring during the course of MS have
been correlated with physical disability and cognitive
impairment and, overall, have been of great relevance
for understanding the pathophysiology of MS and
for monitoring treatment efﬁcacy in clinical trials.3 4
In a complex disease such as MS, however, brain
volume loss might be due to several mechanisms.
These include not only tissue loss (ie, loss of myelin,
glial cells, neurons and axons due to the inﬂamma-
tory demyelination and neurodegeneration), but also
change in non-tissue components (ie, ﬂuids shift due
to inﬂammation).5–9 The respective contribution of
each component to brain volume loss may depend on
many factors, such as disease stage, brain region
affected, type of pharmacological treatment, presence
of comorbidities and other factors unrelated to the
disease.10 In addition, capturing temporal patterns of
structural brain changes requires adequate MRI pro-
tocols and accurate and robust image analysis tools.
In this context, it might be challenging the use of
MRI-based assessments on an individual basis to reli-
ably classify participants into patient versus normal,
as opposed to assessing signiﬁcant group differences.
We propose here a study aiming at assessing
whether it is feasible to achieve individual charac-
terisation of brain atrophy rates in patients with
MS by quantifying interindividual variations and
group overlaps, taking advantage of MRI measure-
ments obtained longitudinally over long follow-up
periods (up to 12 years) using the same MRI proto-
col on the same scanner. The main goal was to
establish speciﬁc cut-offs of brain atrophy rates able
to identify subjects with a ‘physiological’ or ‘patho-
logical’ brain volume loss over time.
MATERIALS AND METHODS
Study population
This is a study based on the analysis of longitudinal
MRI data sets (at least 2 paired scans) of patients
with MS and healthy controls (HC), which were
acquired between January 2000 and December 2013
at the MR center of the University of Siena as part of
other research studies. Patients (n=206, 146/60
women/men; age: mean 37 years, range 18–63 years;
MS type: 180 relapsing–remitting (RR, 87%), 14 sec-
ondary progressive (SP, 7%) and 12 primary progres-
sive (PP, 6%)) were consecutively recruited among
those who were referring to the MS Clinics of the
Universities of Siena and Florence, and the hospital
of Empoli during the study period. During the same
period, HC (n=35, 20/15 women/men; age:
mean=37 years, range 21–60 years) were recruited
from laboratory and hospital workers and were
included in the group if they had normal neurological
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examination and no history of neurological disorders. The
minimum between-scan interval for patients with MS and HC was
12 months (MS patients: mean follow-up=7.5 years, range 1–
12 years; HC: mean follow-up=6.3 years, range 1–12 years). The
mean number of paired scans was 2.6 (range 1–8) for patients
with MS and 1.5 (range 1–4) for HC. The mean time interval
between the paired scans was 4 years (SD=3 years) for patients
with MS and 4.9 years (SD=4 years) for HC. For patients with
MS, there was no limitation for the Expanded Disability Status
Scale (EDSS)11 score (mean=2.25, range 0–8) and disease dur-
ation (mean=6 years, range 0–32 years) at study entry. An EDSS
assessment was performed at the time of each MRI visit.
Disease-modifying treatments (DMTs) were used in 175 (85%)
patients during the study period, while 31 (15%) patients did not
receive any DMT during the study period with the exception of
the intravenous administration of methylprednisolone during
acute relapses.
The study received approval from the local ethics committee
and written informed consent was obtained from all study
participants.
MRI data and analyses
All MRIs were acquired at the MR center of the University of
Siena using a 1.5 T Philips Gyroscan (Philips Medical Systems,
Best, The Netherlands) and the same MRI protocol, as part of
previous research projects. Identical conventional T1-weighted
(T1-W) gradient-echo images used for the brain volume analysis
(repetition time (TR)/echo time (TE)=35/10 ms, 256×256
matrix, 1 signal average, 250 mm ﬁeld of view, 50 slices of
3 mm thickness, axial orientation) were acquired in each partici-
pant and for each time point. Periodical quality control sessions
and no major hardware upgrades were performed on the MR
scanner during the study period.
Global brain volume changes over time were quantiﬁed using
the SIENA method,12 part of the FMRIB Software Library
(FSL; http://www.fmrib.ox.ac.uk/fsl/).13 14 This registration-
based method uses images from two time points to assess brain
volume changes by directly estimating the local shifts in brain
edges across the entire brain and then converting the edge dis-
placement into a global estimate of percentage brain volume
change (PBVC) between the two time points. An automated
procedure of brain extraction able to improve the removal of
eyeballs and the remaining non-brain tissues15 was implemented
in SIENA for a more accurate estimation of brain atrophy.
Statistical analysis
Annualised PBVC (PBVC/y) was calculated for each participant as
the slope of the regression line ﬁtted to all the PBVCmeasurements
for that participant, with the ﬁrst available scan as the ﬁrst time
point, assuming a linear change over time. A weighted mean of
PBVC/y in patients with MS and HC was calculated, with weights
proportional to the follow-up duration (ie, higher weights were
given to PBVC obtained from longer follow-up periods). Weights
were calculated as the follow-up duration (expressed in years)
divided by two, in order to account for correlated information
within participants. Sensitivity analyses using no weights or weights
equal to follow-up duration were performed. A brain atrophy rate
cut-off, which simultaneously maximises the sensitivity and the spe-
ciﬁcity of PBVC/y in discriminating on an individual basis patients
with MS from HC, was estimated by a weighted receiver operating
characteristic (ROC) analysis and quantiﬁed by the area under the
curve (AUC).
Change in annualised EDSS (EDSS/y) was calculated for each
participant as the slope of the regression line ﬁtted to all the
EDSS measurements for that participant, assuming a linear
change over time according to the same procedure used for
PBVC/y. The correlation of PBVC/y with EDSS/y worsening
over time was tested at the univariate analysis by the Pearson
correlation coefﬁcient and at the multivariate analysis by a
linear model adjusted for baseline characteristics (age, disease
duration, EDSS, disease type). The difference in EDSS worsen-
ing between patients with a PBVC/y higher and lower than
0.4% was tested by a Student t test and by a linear model adjust-
ing for baseline characteristics.
All the analyses were run using SPSS V.21.0 (SPSS Inc
Chicago, Illinois, USA) and R software.
RESULTS
Distribution of PBVC/y in HC and patients with MS
Of 545 paired T1-W images for patients with MS and 53 for HC,
four scans of three patients with MS and two scans of one HC
were excluded from the analysis because of unsatisfactory quality.
Using a linear regression analysis, PBVC/y was calculated for
each participant (ﬁgure 1) as the slope of the regression line of
PBVC over time. The average (±SD) of these values, weighted
on the follow-up length, was −0.51%±0.27% in patients with
MS and −0.27%±0.15% in HC (p<0.0001). The observed
(histogram) and theoretical (normal curve) distribution of
PBVC/y is reported in ﬁgure 2A.
Figure 1 ‘Spaghetti’ plots reporting, with different colours, the percent brain volume change (PBVC) between every time point for each healthy
control (HC; left panel) and each patient with multiple sclerosis (MS; right panel) with the ﬁtted average slope (black line).
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There was a signiﬁcant age-related difference of PBVC/y in HC,
but this was not observed in patients with MS: PBVC/y was
−0.20%±0.13% in HC younger than 35 years and −0.32%
±0.14% in HC older than 35 years (p=0.02); PBVC/y was
−0.52%±0.28% in patients with MS younger than 35 years and
−0.51%±0.28% in patients with MS older than 35 years
(p=0.8). There were no signiﬁcant differences of PBVC/y between
patients with MS who were in a relapsing form (−0.52%±0.29%)
and those who were in a progressive form (−0.45%±0.18%,
p=0.2) at baseline, and between patients with MS who were not
on DMT (−0.43%±0.28%) and those who were on DMT during
the follow-up (−0.53%±0.27%, p=0.1; table 1).
ROC analysis
The ROC curve relative to PBVC/y in patients with MS and HC
is reported in ﬁgure 2B. The AUC was 0.77 (0.74–0.81) and the
cut-off simultaneously maximising the sensitivity and speciﬁcity
of PBVC/y in discriminating patients with MS from HC was
−0.37%. Such a cut-off value gives an observed sensitivity of
67% and a speciﬁcity of 80% in discriminating patients with
MS from HC based on their PBVC/y in our cohort. Using the
theoretical distribution ﬁtted to the data, the sensitivity was
69% and the speciﬁcity was 74%.
When including only patients with relapsing–remitting mul-
tiple sclerosis (RRMS; n=180), the AUC was 0.78 (0.74–0.81)
and the best cut-off, as previously deﬁned, was again −0.37%.
In this cohort, using this cut-off value for PBVC/y, the sensitivity
was 67% and the speciﬁcity was 80% in discriminating patients
with MS from HC.
Similar results were obtained in the sensitivity analyses using dif-
ferent weighting systems: the AUC using no weights was 0.78
(0.72–0.85) and the cut-off was −0.32%; the AUC using the full
follow-up duration as the weight was 0.77 (0.75–0.80) and the
cut-off was −0.37%. Results did not chance by including only
patients with RRMS (AUC=0.78 (0.74–0.81); cut-off=−0.37%).
Defining ranges of PBVC/y
The main aim of this analysis was to deﬁne ranges of ‘physio-
logical’ or ‘pathological’ PBVC/y, and this could be achieved
using the distribution of PBVC/y in HC and patients with MS.
The ‘pathological range’ can be deﬁned as the one containing all
the values of PBVC/y that minimise the probability to deﬁne as
‘pathological’ an HC (ie, the value that maximises the speciﬁ-
city). Consequently, the ‘physiological range’ can be deﬁned as
the range of PBVC/y values below the threshold deﬁning the
pathological range. In table 2, the ranges giving an expected
(and observed) 95%, 90% and 80% speciﬁcity to deﬁne a
Figure 2 In (A), observed frequency distribution of annualised percent brain volume change (PBVC/y) in patients with multiple sclerosis (MS; top
panel) and healthy controls (HC, lower panel) with their ﬁtted normal distribution and the optimal cut-off discriminating the two groups as
estimated by the receiver operating characteristic (ROC) analysis. In (B), ROC curve reporting sensitivity and speciﬁcity in discriminating patients with
MS and HC according to different cut-off levels of their PBVC/y.
Table 1 Values of PBVC/y according to age, MS type and use of
DMTs during follow-up
Subject characteristics Mean PBVC/y (SD), % p Value
Age at baseline (HC)
≤35 (n=16) −0.20 (0.13) 0.02
>35 (n=19) −0.32 (0.14)
Age at baseline (patients with MS )
≤35 (n=92) −0.52 (0.28) 0.8
>35 (n=114) −0.51 (0.28)
MS type
Relapsing (n=180) −0.52 (0.29) 0.2
Progressive (n=26) −0.45 (0.18)
DMTs during follow-up
No (n=31) −0.43 (0.28) 0.1
Yes (n=175) −0.53 (0.27)
DMTs, disease-modifying treatments; HC, healthy controls; MS, multiple sclerosis;
PBVC/y, annualised percent brain volume change.
Table 2 Cut-off values that identify PBVC/y (as measured by
SIENA) distinguishing HC from patients with MS with specificity
ranging from 95% to 80% and the corresponding levels of
sensitivity
PBVC cut-offs, % Specificity (%) Sensitivity (%)
−0.52 95% (observed 97) 49% (observed 44)
−0.46 90% (observed 91) 56% (observed 48)
−0.40 80% (observed 86) 65% (observed 61)
Values of probability are estimated from the theoretical normal distributions of PBVC/
y in HC and patients with MS (in brackets, those actually observed are reported).
Note that the observed sensitivity was very similar when only patients with RRMS
(n=180) were considered.
HC, healthy controls; MS, multiple sclerosis; PBVC/y, annualised percent brain volume
change; RRMS, relapsing–remitting multiple sclerosis.
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patient as having a pathological PBVC/y are reported. Expected
values are calculated using the area under the normal distribu-
tion with the mean and the SD obtained in the HC group,
while observed values are the proportion of patients actually
observed in our cohort.
According to the observed distributions, a cut-off of PBVC/y
higher than −0.52% (ie, deﬁning as ‘pathological’ a subject with
a yearly brain volume loss higher than −0.52%) can identify a
pathological subject with a 5% rate of ‘false-positive’ results
(ie, a 5% of normal subjects will be deﬁned erroneously as
pathological using this cut-off ), while a cut-off of PBVC/y
higher than −0.46% can identify a pathological subject with a
10% rate of ‘false-positive’ results, and a cut-off of PBVC/y
higher than −0.40% can identify a pathological subject with a
20% rate of ‘false-positive’ results (table 2, ﬁgure 3).
Testing association of the PBVC cut-offs with the rate of
EDSS worsening
The slope of yearly EDSS worsening was estimated for each
patient. The PBVC/y was signiﬁcantly associated with the slope
of EDSS change (r=−0.21, p=0.003), also when adjusting for
age, MS type (relapsing vs progressive), disease duration and
baseline EDSS in a multivariate model (partial r=−0.23,
p=0.001). The PBVC/y was dichotomised according to the
−0.4% cut-off to test whether patients with MS with a change in
their brain volume above and below this value have a different
EDSS worsening over time. The change in EDSS/y was signiﬁ-
cantly different between patients with a PBVC/y higher than
−0.4% (mean EDSS/y change=0.00 (SD=0.32) and patients
with a PBVC/y lower than −0.4% (mean EDSS/y change=+0.14
(SD=0.35), p=0.003, ﬁgure 4), and the difference remained sig-
niﬁcant after adjusting for age, disease duration, MS type and
baseline EDSS. The same was true when only the patients with
RRMS were considered: the change in EDSS/y was −0.10
(SD=0.20) for patients with PBVC/y higher than −0.4% and was
+0.07 (SD=0.30), p<0.001 for patients with a PBVC/y lower
than −0.4%.
DISCUSSION
Despite the relevance demonstrated by a number of research
studies, brain volumetric MRI has yet to be widely translated
into clinical practice. Generally, this is due to several factors
such as, for example, the variation in imaging protocols (MRI
parameters, spatial distortions, motion artefacts, etc) or the lack
of normative data acquired with the same MR protocol used for
patients who would allow the physician to interpret biomarker
values in patient care. Moreover, even when using fully auto-
mated computerised methods, anatomical knowledge has always
to be the foundation of quality control (ie, visual inspection of
the results), as it would happen for any type of quantitative ana-
lysis. All these issues were taken into account in the present
study. It is more difﬁcult to control for factors such as lifestyle
(eg, alcohol, smoking, dehydration), genetics (eg, apolipoprotein
E expression) and concomitant drug therapies and pathophysio-
logical conditions (eg, diabetes, cardiovascular risk), which may
affect the accuracy of brain volume measurements, particularly
in the single-patient assessment.1 Moreover, brain volume loss
progresses over time and may be more pronounced when ageing
is complicated by other risk factors, such as smoking, diabetes
and other cardiovascular risk factors.16
Despite the above limitations, advances in computational
technology are paving the way for a more convincing clinical
use of MRI-based brain volumetry in a number of neurological
disorders.1 17 This is, in principle, more difﬁcult in a disease
with a complex pathological substrate such as MS where brain
volume changes reﬂect not only tissue loss due to the inﬂamma-
tory demyelination and neurodegeneration, but also ﬂuid shift
due to inﬂammation.5–9 This makes it difﬁcult to use individua-
lised longitudinal brain volume assessments in a clinical setting
since physiological variability and measurement errors may add
to the biological variations related to the disease.
In this study, we made an attempt to control for many of the
above limitations. First, we used a longitudinal data set of
patients with MS and HC that was acquired with the same MR
scanner (which did not have major hardware upgrades during
the more than 10-year study period) and by using an identical
protocol over the long follow-up. Second, a widely used soft-
ware package (ie, SIENA),18 which has shown to be a highly
sensitive, reproducible and accurate method in previous
studies,19–32 was employed for measuring brain volume
changes. Third, processes related to inﬂammation (ie, ‘pseudoa-
trophy’) or the presence of concomitant pathophysiological con-
ditions that can complicate the interpretation of brain volume
measurements in the single patient were minimised by the long-
term follow-up (ranging from 1 to 12 years, with a mean of
7.5 years in patients with MS and 6.3 years in HC); the long-
term follow-up also minimises the impact of the biological vari-
ability and measurement error on the estimate of the yearly rate
of brain volume loss. Finally, we implemented a statistical model
that was able to provide values of brain volume rates that could
discriminate HC from patients with MS on a single-patient
basis. Results show a range of brain volume rates (see table 2)
that could classify a single patient with MS as being in a physio-
logical (ie, in the range of HC) or pathological (ie, in the range
of MS) rate of brain volume loss with a certain degree of sensi-
tivity and speciﬁcity. Interestingly, these values are not different
from those published previously by using the same approach as
physiological16 33–35 or pathological19–32 brain volume loss. In
particular, our study suggests different values of PBVC/y that
can deﬁne a pathological range at different levels of speciﬁcity
(ie, ‘pathological’ rates could be deﬁned as above −0.52% with
a speciﬁcity of 95%, above −0.46% with a speciﬁcity of 90%
and above −0.40% with a speciﬁcity of 80%). Interestingly,
increasing age, which did not show a role in the PBVC/y differ-
ence across patients with MS, did not inﬂuence such cut-off
values. In contrast, treatment effect might have inﬂuenced them
(most of the population with MS reported here was treated with
DMT for most of the follow-up), but this should have worked
in the direction of making the general cut-offs more conserva-
tive on the pathological side.
Establishing cut-offs able to discriminate between physio-
logical and pathological rates in patients with MS is not an easy
task. The relatively large overlap of the PBVC distribution
between patients with MS and HC conﬁrms these difﬁculties
(see ﬁgure 3). Thus, we based our statistical model on the speci-
ﬁcity we can reach in deﬁning a subject in the ‘pathological’
range rather than on the sensitivity we can reach in deﬁning a
subject in the ‘physiological’ range. Indeed, a patient with MS
does not necessarily have pathological brain volume loss in a
given follow-up period, and in fact the overlap of the distribu-
tions of HC and patients with MS is large on the right, ‘physio-
logical’, side. In contrast, all HC are supposed to have a
physiological rate of PBVC, thus making possible to base the
deﬁnition of “pathological” on values that HC do not have or
can have with a very low probability.
Several lines of evidence challenge the classical view of MS as
a disease leading exclusively to the formation of focal WM
lesions, giving paramount relevance to the diffuse pathology
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involving grey and WM.36 37 Brain volume loss can be consid-
ered the ultimate consequence of this diffuse damage, and since
this has relevant clinical implications on disease progression,3
the deﬁnition of pathological cut-offs for the rate of brain
volume loss in a patient with MS could be of great help in a
clinical setting with potential therapeutic impact. Indeed, rates
of brain volume loss have been shown to provide additional
complementary information in explaining treatment effect on
disability in a recent meta-analysis of randomised clinical
trials.38 Even more importantly, brain volume loss rates might
be very helpful in expanding the concept of no evident disease
activity, an emerging target for treatment in MS where a
Figure 3 Graphical representation of
the speciﬁcity given by each cut-off
value of annualised percent brain
volume change (PBVC/y) in
distinguishing patients with multiple
sclerosis (MS) and healthy controls
(HC), with the ﬁtted distribution of
PBVC/y in each group, and the overlap
of the two distributions.
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measure of diffuse brain damage needs to be added to focal
MRI (ie, WM lesions) and clinical (ie, relapses and disability)
measures. In this context, on the basis of the present analysis,
we can provide evidence-based criteria to choose cut-offs of
PBVC/y deﬁning patients with no evidence of brain volume loss.
Indeed, according to the present data, a PBVC/y of −0.4%
could discriminate the presence or absence of ‘pathological’
brain volume loss with high speciﬁcity and good sensitivity
(table 2). This speciﬁc cut-off was demonstrated to be clinically
relevant, since patients with brain volume loss higher than
−0.4% had a signiﬁcant EDSS worsening than those with a
brain volume loss lower than −0.4% (see ﬁgure 4).
Further, it must be stressed here that while the values of brain
volume loss provided in this study for both the groups with
patients with MS and HC are similar to those previously pub-
lished by using the same measurement method (ie, the SIENA
method),16 19–35 they cannot be extended to other methods.
Moreover, while in this study biological variability and measure-
ment errors were minimised by the long-term follow-up, owing
to the use of an accurate quality control and a homogeneous
single-centre data set, these sources of errors could be magniﬁed
in a real-world setting where the follow-up is signiﬁcantly
shorter and different MR sequences and multicentre data sets
are used. Interestingly, a recent meta-analysis that integrated
ﬁndings from 56 different MRI studies on whole brain volume
changes in healthy individuals reported values which were not
very different from those reported in this study, despite the het-
erogeneity in the MRI acquisition and postprocessing. It is true,
however, that this aspect needs to be further assessed in pro-
spective multicentre studies, possibly focusing on healthy indivi-
duals to establish normative values for brain volume changes
from a large population and take into account all possible con-
founding factors.
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